Search

Search Constraints

You searched for: Author/Creator Dayal, Satish

Search Results

1. [P1–043]: ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG. (1st July 2017)

2. [P2–003]: ELENBECESTAT PHARMACOKINETIC DRUG‐DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS. (1st July 2017)

3. Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study. (June 2022)

7. Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females. Issue 9 (9th June 2021)

8. Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant. Issue 6 (17th January 2021)

9. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. Issue 1 (17th June 2020)

10. The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 1. Issue 7 (11th April 2014)